Laurus Labs receives approval for anti-malaria tablets

Leading pharma company Laurus Lab received two USFDA approvals, the company informed post market hours on Monday. The products will be manufactured at the company's plant in Visakhapatnam. 

The company has received final approval for hydroxychloroquine tablets 200 mg from the United States Food and Drug Administration (USFDA). The medication is used for the treatment of Malaria and in combination with other medications, to treat certain auto-immune diseases including lupus, rheumatoid arthritis (when other medications have not worked or cannot be used). The hydroxychloroquine tablet 200 Mg is therapeutically equivalent of Plaquenil Tablets from Concordia Pharmaceuticals, Incorporated.

While the second is a tentative ANDA approval for Abacavir, Dolutegravir, and Lamivudine tablets Tablets 600 mg/50 mg/300 mg.

The products will be manufactured at the company's plant located at Atchutapuram, Visakhapatnam.

On Monday, the stock of Laurus Labs Limited closed at Rs. 363.85 per share, up by Rs. 13.75 or 3.93 per cent on BSE, on the day when Nifty Pharma was moving northward and closed up by 1.52 per cent. The stock opened at Rs. 360.00 and hit an intraday high of Rs. 371.40. The benchmark Nifty50 gained 140.90 points or 1.28 per cent and closed at 11,176.30.